Literature DB >> 26259998

Prevalence of Female Urinary Incontinence in the General Population According to Different Definitions and Study Designs.

Dina Bedretdinova1, Xavier Fritel2, Henri Panjo3, Virginie Ringa3.   

Abstract

BACKGROUND: Estimates of the prevalence of female urinary incontinence (UI) vary widely.
OBJECTIVE: To estimate UI prevalence among women in France using data from five national surveys and analyse prevalence differences among the surveys according to their design (representative sample or not, survey focused on UI or not) and UI definition (based on symptoms or disease perception). DESIGN, SETTING, AND PARTICIPANTS: Data came from two representative telephone surveys, Fecond (5017 women aged 15-49 yr) and Barometer (3089 women aged 40-85 yr), general and urinary postal surveys of the GAZEL cohort (3098 women aged 54-69 yr), and the web-based NutriNet survey (85,037 women aged 18-87 yr). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Definitions of UI based on the International Conference on Incontinence Questionnaire UI short form (ICIQ-UI-SF) and on a list of health problems were considered. We compared age-adjusted prevalence rates among studies via logistic regression and generalised linear models. RESULTS AND LIMITATIONS: Overall, 13% of the women in Fecond, 24% in Barometer, 15% in the GAZEL general survey, 39% in the GAZEL urinary survey, and 1.5% in the NutriNet survey reported any UI. Prevalence rates in representative samples with the same UI definition (ICIQ-UI-SF) were concordant. UI prevalence in the representative samples was 17%. The estimated number of women in France with UI was 5.35 million (95% confidence interval [CI] 5.34-5.36 million) for any UI and 1.54 million (95% CI 1.53-1.55 million) for daily UI. For the GAZEL sample, UI prevalence was lower but UI severity was greater for responses to a questionnaire with the list-based UI definition rather than to a questionnaire with the ICIQ-UI-SF-based definition. In all surveys, information about UI was self-reported and was not validated by objective measurements.
CONCLUSIONS: UI definitions and sampling strategies influence estimates of UI prevalence among women. Precise estimates of UI prevalence should be based on non-UI-focused surveys among representative samples and using a validated standardised symptom-based questionnaire. PATIENT
SUMMARY: We looked at estimates of urinary incontinence (UI) prevalence in studies with different designs and different UI definitions in a large population of French women. We found that estimates varied with the definition and the design. We conclude that the most precise estimates of UI prevalence are obtained in studies of representative populations that are not focused on UI and use a validated international standard questionnaire with sufficient details to allow grading of UI severity. Most women reported rare urine leakages involving small amounts of urine with little impact on their quality of life.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cross-sectional study; Epidemiology; Prevalence; Questionnaire; Symptoms; Telephone-based study; Urinary incontinence; Web-based study; Women

Mesh:

Year:  2015        PMID: 26259998     DOI: 10.1016/j.eururo.2015.07.043

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  18 in total

1.  Urinary incontinence among Muslim women in Israel: risk factors and help-seeking behavior.

Authors:  Yulia Treister-Goltzman; Roni Peleg
Journal:  Int Urogynecol J       Date:  2017-08-04       Impact factor: 2.894

2.  Female double incontinence: prevalence, incidence, and risk factors from the SABE (Health, Wellbeing and Aging) study.

Authors:  Denise R Yuaso; Jair L F Santos; Rodrigo A Castro; Yeda A O Duarte; Manoel J B C Girão; Bary Berghmans; José Tadeu N Tamanini
Journal:  Int Urogynecol J       Date:  2017-06-15       Impact factor: 2.894

Review 3.  Urinary incontinence in women.

Authors:  Yoshitaka Aoki; Heidi W Brown; Linda Brubaker; Jean Nicolas Cornu; J Oliver Daly; Rufus Cartwright
Journal:  Nat Rev Dis Primers       Date:  2017-07-06       Impact factor: 52.329

4.  Effectiveness of pelvic floor muscle training and bladder training for women with urinary incontinence in primary care: a pragmatic controlled trial.

Authors:  Camila Teixeira Vaz; Rosana Ferreira Sampaio; Fernanda Saltiel; Elyonara Mello Figueiredo
Journal:  Braz J Phys Ther       Date:  2019-01-19       Impact factor: 3.377

5.  Urinary incontinence status and risk factors in women aged 50-70 years: a cross-sectional study in Hunan, China.

Authors:  Chen Xu; Mingzhu Chen; Jingxia Fu; Yanting Meng; Si Qin; Yang Luo
Journal:  Int Urogynecol J       Date:  2020-02-24       Impact factor: 2.894

6.  The epidemiology of urinary incontinence: a case still open.

Authors:  Maurizio Serati; Fabio Ghezzi
Journal:  Ann Transl Med       Date:  2016-03

Review 7.  Prevalence, incidence and bothersomeness of urinary incontinence in pregnancy: a systematic review and meta-analysis.

Authors:  Heidi F A Moossdorff-Steinhauser; Bary C M Berghmans; Marc E A Spaanderman; Esther M J Bols
Journal:  Int Urogynecol J       Date:  2021-01-13       Impact factor: 2.894

Review 8.  Urinary Incontinence as a Predictor of Death: A Systematic Review and Meta-Analysis.

Authors:  Gregor John; Claire Bardini; Christophe Combescure; Patrick Dällenbach
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

9.  Population-Level Prevalence, Bother, and Treatment Behavior for Urinary Incontinence in an Eastern European Country: Findings from the LUTS POLAND Study.

Authors:  Mikolaj Przydacz; Marcin Chlosta; Piotr Chlosta
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

10.  Women's barriers for contacting their general practitioner when bothered by urinary incontinence: a population-based cross-sectional study.

Authors:  Dorte Ejg Jarbøl; Peter Fentz Haastrup; Sanne Rasmussen; Jens Søndergaaard; Kirubakaran Balasubramaniam
Journal:  BMC Urol       Date:  2021-07-12       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.